Ageless Pep Academy Clinical Education · Licensed Prescribers

PMID-28981741 – Cancer Risk Associated with Calcitonin Use Population Cohort

PMID-28981741 – Cancer Risk Associated with Calcitonin Use Population Cohort

Sun LM, Lin MC, Muo CH, et al. Comparative risks for cancer associated with use of calcitonin, bisphosphonates or selective estrogen receptor modulators among osteoporosis patients: a population-based cohort study. Jpn J Clin Oncol. 2017;47(10):935-941.

Quick Reference

Property Value
PMID 28981741
DOI 10.1093/jjco/hyx101
Year 2017
Journal Japanese Journal of Clinical Oncology
Study Type Observational / Cohort
Evidence Level III
Sample Population-based cohort from Taiwan National Health Insurance Research Database
Peptide(s) Studied Calcitonin

Key Findings

  • Compared cancer incidence among osteoporosis patients using calcitonin, bisphosphonates, or SERMs using Taiwan's National Health Insurance Research Database
  • Calcitonin use was associated with a numerically higher overall cancer risk compared to bisphosphonates and SERMs, though results varied by cancer type
  • The study contributes to the post-marketing safety evaluation initiated after the 2013 FDA/EMA reviews flagged a possible cancer association with calcitonin
  • Results must be interpreted cautiously given the observational design and potential for confounding by indication
  • No definitive causal link between calcitonin and cancer was established

Study Design

Population-based retrospective cohort study using Taiwan's National Health Insurance Research Database. Identified osteoporosis patients who received calcitonin, bisphosphonates, or SERMs. Cancer incidence was tracked through cancer registry linkage. Propensity score matching and Cox proportional hazards models were used to compare cancer risks across treatment groups. Adjusted for age, sex, comorbidities, and healthcare utilization.

Limitations

  • Retrospective observational design — cannot establish causation
  • Potential for confounding by indication (calcitonin users may differ systematically from bisphosphonate/SERM users)
  • Asian population — may not generalize to other ethnic groups
  • Limited information on calcitonin dose, duration, and formulation (nasal vs injectable)
  • Cancer latency periods may exceed the observation window
  • Database studies cannot capture over-the-counter medication use or lifestyle factors

Clinical Relevance

This study is part of the post-2013 pharmacovigilance literature evaluating the cancer signal that led the FDA and EMA to issue safety communications about calcitonin. In 2013, the EMA recommended restricting calcitonin nasal spray to short-term use only (up to 4 weeks for acute vertebral fracture pain), citing a meta-analysis showing a small but statistically significant increase in cancer risk (OR ~1.2-2.4 across different analyses). The FDA conducted a parallel review but did not withdraw intranasal calcitonin from the US market, instead recommending that benefits and risks be weighed individually. This population-level cohort study adds real-world data to the discussion but does not resolve the causal question. Current practice limits calcitonin use to short courses for fracture pain, with the cancer risk as a documented safety consideration.

Related

#research #cohort #observational #calcitonin #evidence-level-III